Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera.
Quintás-Cardama
Alfonso
A
Verstovsek
Srdan
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D053614:Janus Kinase 2 / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D010292:Paresthesia / Q000139:chemically induced; D010865:Pilot Projects; D011087:Polycythemia Vera / Q000235:genetics / Q000628:therapy*; D013922:Thrombocytosis / Q000235:genetics / Q000628:therapy*; D013997:Time Factors
D007155:Immunologic Factors; D016898:Interferon-alpha; C507924:JAK2 protein, human; D053614:Janus Kinase 2